1-3 of 3
Ender Soydan, MD
Close
Sort by
Journal Articles

Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Vildan Ozkocaman, MD, Pervin Topcuoglu, MD, Berna Evranos, MD, Merih Kizil, MD, Aynur U. Bilgin, MD, Mutlu Arat, MD, Muhit Ozcan, MD, Onder Arslan, MD, Gunhan Gurman, MD, Osman Ilhan, MD
Journal: Blood
Blood (2007) 110 (11): 5096.
https://doi.org/10.1182/blood.V110.11.5096.5096
Published: 2007
Journal Articles

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Selami Kocak Toprak, MD, Merih Kizil, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD
Journal: Blood
Blood (2005) 106 (11): 5117.
https://doi.org/10.1182/blood.V106.11.5117.5117
Published: 2005
Journal Articles

The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.

Pervin Topcuoglu, MD, Mutlu Arat, MD, Tugce Bolukbasi, MD, Ender Soydan, MD, Yesim Ozer, MD, Muhit Ozcan, MD, Gunhan Gurman, MD, Taner Demirer, MD, Hamdi Akan, MD, Meral Beksac, MD, Onder Arslan, MD, Osman Ilhan, MD
Journal: Blood
Blood (2004) 104 (11): 5146.
https://doi.org/10.1182/blood.V104.11.5146.5146
Published: 2004